Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

50.200
+4.60010.09%
Volume:13.48M
Turnover:655.49M
Market Cap:333.18B
PE:36.42
High:50.400
Open:46.080
Low:45.380
Close:45.600
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:5.00
T/O Rate:5.22%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:4.42
PE(LYR):36.42
PS:9.10

Loading ...

Movement Alert|HENGRUI PHARMA Falls 3.17% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure Despite Multiple Positive Catalysts

Market Focus
·
Jul 30

Hengrui Pharma Wins China Regulator's Nod for Three Drugs

MT Newswires Live
·
Jul 30

Capital Group Boosts Stake in Hengrui Pharma with 752,200 Share Purchase

Deep News
·
Jul 30

Hengrui Pharma Secures NMPA Nod for China’s First Home-grown Long-Acting Insulin Analog

Bulletin Express
·
Jul 29

Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval

Stock News
·
Jul 29

Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog

Stock News
·
Jul 29

Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads

Stock News
·
Jul 29

Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission

Stock News
·
Jul 29

AH Premium Data Overview: July 29 Market Close

Stock News
·
Jul 29

AH Share Premium and Discount Report for July 28

Stock News
·
Jul 28

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Hypertension Drug Trial

MT Newswires Live
·
Jul 28

Hengrui Pharmaceuticals' Pancreatic Cancer Drug Gets US FDA Orphan Status

MT Newswires Live
·
Jul 28

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live
·
Jul 27

Citigroup’s Short Position in H-shares of Jiangsu Hengrui Pharmaceuticals Decreases to 2.53% on July 20 from 3.07% - HKEX Filing

THOMSON REUTERS
·
Jul 24

Cross-Listed Stock Premium Report: Closing Data for July 24

Stock News
·
Jul 24

Hengrui Pharma gains NMPA approval for camrelizumab-famitinib as first-line treatment in recurrent/metastatic cervical cancer

Bulletin Express
·
Jul 23

AH Share Premium and Deviation Data for July 22nd

Stock News
·
Jul 22

Movement Alert|Hengrui Pharma Falls 3.22% in Regular Trading, Trading at HK$55.6

Market Focus
·
Jul 21

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

Movement Alert|Hengrui Pharma Rises 3.36% in Regular Trading, Pharmaceutical Sector Rebounds as Buyback Program Advances

Market Focus
·
Jul 20